Speaker illustration

Doctor Baravan Al-Kassou

University hospital Bonn, Bonn (Germany)

Member of:

European Society of Cardiology

Dr. Baravan Al-Kassou is an interventional cardiologist and clinical researcher at the Heart Center of the University Hospital Bonn, Germany. His research focuses on structural heart interventions, particularly in patients with severe aortic stenosis. His efforts aim to optimize risk stratification and enhance the safety of interventional cardiac procedures. Additionally, his research addresses optimal treatment strategies and timing for patients with multiple native valvular heart diseases. Furthermore, Dr. Al-Kassou is actively engaged in investigating the complex genetic architecture underlying aortic valve diseases, including bicuspid aortic valve and aortic stenosis. He serves as a Project Leader of GUARD (Genes Underlying Aortic Valve Disease), a project funded by the German Research Foundation. Through this initiative, Dr. Al-Kassou leads efforts to elucidate the genetic risk factors associated with the development of aortic diseases.

Cholesterol crystal dissolution rate of serum is associated with iliofemoral calcification and predicts outcomes in patients undergoing TAVR

Event: ESC Congress 2023

Topic: Intervention

Session: Advances and remaining challenges in percutaneous valve intervention

Thumbnail

Myocardial infarction with ST-segment elevation caused by caseous mitral annular calcification

Event: ESC Congress 2023

Topic: Clinical

Session: Coronary disorders

Thumbnail

Hemodynamic effects and challenges of combined use of extracorporeal membrane oxygenation and ventricular support for refractory cardiogenic shock: a case report

Event: ESC Congress 2023

Topic: Clinical

Session: Acute cardiac care (1)

Thumbnail

Safety and efficacy of protamine administration for prevention of bleeding complications in patients with recent PCI undergoing TAVR

Event: ESC Congress 2023

Topic: Intervention

Session: Walking the line between bleeding and thrombosis in valvular heart disease

Thumbnail

The association of CT-assessed fat-free muscle fraction with frailty and malnutrition and the predictive value of their combination in patients undergoing TAVR

Event: ESC Congress 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Predictors of outcomes in transcatheter aortic valve implantation

Thumbnail

Incidence and management of multiple native valvular heart disease in patients undergoing TAVR: Impact of staged valvular interventions on outcomes

Event: ESC Congress 2023

Topic: Intervention

Session: Predictors of outcomes in transcatheter aortic valve implantation

Thumbnail

Optimal protamine-to-heparin dosing ratio for the prevention of bleeding complications in patients undergoing TAVR - a multicentre experience

Event: ESC Congress 2022

Topic: Intervention

Session: Challenges in transcatheter aortic valve intervention

Thumbnail

Novel assay for quantifying the cholesterol crystal dissolution capacity of serum predicts outcomes in patients with severe aortic stenosis undergoing TAVR

Event: ESC Congress 2022

Topic: Aortic Valve Stenosis

Session: Pathophysiology and disease progression in aortic stenosis

Thumbnail

Impact of frailty status on 30-day mortality in patients with valvular heart disease undergoing percutaneous transcatheter valve interventions

Event: ESC Congress 2019

Topic: Aortic Valve Intervention

Session: Non-coronary cardiac intervention

Thumbnail

Prognostic value of logistic EuroSCORE and STS-PROM in a recent patient cohort undergoing TAVI with next generation transcatheter heart valves

Event: ESC Congress 2018

Topic: Intervention

Session: Outcome prediction tools after valve intervention

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb